Does Medicare Advantage Cover Armour Thyroid?

How Medicare Advantage Drug Coverage Works for Thyroid Medications

Medicare Advantage (Medicare Part C) plans are offered by private insurers contracted with the Centers for Medicare & Medicaid Services (CMS). When a plan includes Part D prescription drug benefits, it must cover at least two drugs in every therapeutic category and pharmacologic class, per CMS formulary requirements. Thyroid preparations fall under the endocrine therapeutic class, so every Part D formulary must include thyroid hormone options.

Part D vs. Part B Coverage

Armour Thyroid is an oral, self-administered medication. That places it under Part D (outpatient prescription drug coverage), not Part B (physician-administered drugs). Patients enrolled in a standalone Medicare Advantage plan without Part D benefits would need a separate Part D plan or would pay out of pocket.

Why Carrier Matters

CMS sets minimum coverage rules, but each Medicare Advantage insurer builds its own formulary. UnitedHealthcare, Humana, Aetna, Blue Cross Blue Shield affiliates, and Cigna each assign Armour Thyroid to different tiers and attach different utilization management controls. A patient switching Medicare Advantage carriers during Annual Enrollment (October 15 through December 7) could see their Armour Thyroid copay change by $30 to $60 per month depending on tier placement.

What Formulary Tier Is Armour Thyroid on Medicare Advantage Plans?

Armour Thyroid (desiccated thyroid extract, manufactured by Allergan/AbbVie) is a brand-name drug without a generic AB-rated equivalent. Because of this, most Medicare Advantage formularies place it on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). A small number of plans exclude it entirely and cover only synthetic alternatives.

Typical Cost-Sharing by Tier

On Tier 2, expect copays between $30 and $50 for a 30-day supply. Tier 3 placement raises that range to $50 to $80. Plans using coinsurance instead of flat copays may charge 25% to 40% of the negotiated price, which can push monthly costs above $70 during the Initial Coverage Phase.

The Coverage Gap (Donut Hole)

After total drug spending (patient plus plan) reaches $5,570 in 2026, beneficiaries enter the coverage gap. Under the Inflation Reduction Act, out-of-pocket costs in the gap are now capped, but patients on non-preferred brands like Armour Thyroid still pay more during this phase than they would on a generic synthetic T4. Once catastrophic coverage begins (after $2,000 total out-of-pocket spending in 2025+), copays drop to $0 or a small fixed amount under the new IRA Part D redesign.

Prior Authorization Requirements for Armour Thyroid

Many Medicare Advantage carriers require prior authorization (PA) before covering Armour Thyroid. PA criteria typically demand documentation that the patient has tried and failed synthetic levothyroxine, or that a medical reason (allergy, excipient intolerance, persistent symptoms despite adequate TSH levels on levothyroxine) prevents its use.

What Prescribers Need to Submit

A successful PA request generally includes three elements: a current TSH level (drawn within 60 to 90 days), a record of the prior levothyroxine trial (dose, duration, and reason for discontinuation), and a letter of medical necessity from the prescribing clinician. Some carriers also require documentation of free T3 and free T4 levels. Processing time for standard PA requests is 72 hours under CMS Part D rules; expedited requests must be resolved within 24 hours.

Common Reasons for PA Denial

The most frequent denial reason is "preferred alternative available." CMS allows Part D plans to require use of clinically equivalent lower-cost drugs before covering a more expensive option. Levothyroxine costs $4 to $15 per month at most pharmacies, making it 6 to 20 times cheaper than Armour Thyroid at list price. Plans view this cost differential as sufficient justification for step therapy.

A 2013 randomized crossover trial by Hoang et al. (N=70) published in the Journal of Clinical Endocrinology & Metabolism found that desiccated thyroid extract produced 3 lb more weight loss than levothyroxine over 16 weeks, with no difference in TSH normalization, and that 49% of participants preferred desiccated thyroid extract [1]. This trial is frequently cited in appeal letters, though its small sample size limits the strength of the evidence. The American Thyroid Association (ATA) 2014 guidelines acknowledge that some patients report improved well-being on combination T4/T3 therapy but stop short of recommending desiccated thyroid over levothyroxine as first-line treatment [2].

Step Therapy Requirements on Medicare Advantage

Step therapy (also called "fail first") is a utilization management tool that requires patients to try one or more preferred drugs before the plan will approve a non-preferred alternative. For Armour Thyroid, the step therapy sequence on most Medicare Advantage plans looks like this: Step 1 is generic levothyroxine (T4 monotherapy), and Step 2 is Armour Thyroid or another desiccated thyroid product.

How Long the Step 1 Trial Must Last

Most plans require 60 to 90 days on an adequate dose of levothyroxine. "Adequate dose" typically means a dose that brings TSH into the reference range (0.4 to 4.0 mIU/L per most lab assays). If TSH normalizes but the patient still reports fatigue, weight gain, or cognitive symptoms, the prescriber can document "symptomatic despite biochemical euthyroidism" as the step therapy failure criterion.

Exceptions to Step Therapy

CMS requires Part D plans to grant step therapy exceptions when a prescriber provides clinical justification. Under the Medicare Prescription Drug Benefit Manual, Chapter 18, plans cannot force a patient to restart a drug that previously caused an adverse reaction. If a patient's medical record shows prior levothyroxine intolerance (e.g., documented allergic reaction to a dye or filler in the tablet), the plan must waive step therapy. Patients already stable on Armour Thyroid who are newly enrolling in a Medicare Advantage plan can also request a transition supply, typically 30 days, to avoid treatment interruption while PA paperwork is processed.

How to Appeal a Medicare Advantage Denial of Armour Thyroid

If your Medicare Advantage plan denies coverage of Armour Thyroid, you have a structured five-level appeal process defined by federal law. Most denials are resolved at Level 1 or Level 2.

Level 1: Plan Reconsideration

File within 60 days of the denial notice. Submit a written request to the plan's pharmacy benefits department along with a letter of medical necessity from your prescriber. The plan must respond within 7 calendar days (standard) or 72 hours (expedited). Include lab results, documentation of prior levothyroxine failure, and any supporting literature.

Level 2: Independent Review Organization (IRO)

If the plan upholds the denial, request an IRO review. CMS contracts with MAXIMUS Federal Services to conduct independent external reviews of Part D appeals. MAXIMUS physicians who are not affiliated with your plan review your case. The decision is binding on the plan. Turnaround is 7 days for standard and 72 hours for expedited requests. According to CMS data on Part D appeals, roughly 40% to 50% of IRO reviews result in full or partial reversals in favor of the beneficiary.

Levels 3 Through 5

Level 3 goes to an Administrative Law Judge (for claims exceeding $190 in 2026), Level 4 to the Medicare Appeals Council, and Level 5 to federal district court. Armour Thyroid appeals rarely escalate past Level 2 because the drug cost is modest and most plans will approve coverage once an IRO rules in the patient's favor.

Tips for a Stronger Appeal

Reference specific clinical documentation. A TSH of 2.1 mIU/L with persistent fatigue is stronger than "patient doesn't feel well on levothyroxine." Cite the Hoang et al. Crossover trial [1] showing patient preference for desiccated thyroid. Include the ATA guideline acknowledgment that combination T4/T3 therapy may benefit select patients [2]. If possible, attach a free T3 level drawn on levothyroxine showing low-normal values (below 2.5 pg/mL), which supports the clinical rationale for adding T3 via desiccated thyroid.

Armour Thyroid vs. Synthetic Levothyroxine: Cost and Coverage Comparison

Understanding how these two options compare on Medicare Advantage plans helps patients and prescribers manage formulary decisions.

Price Differential

Generic levothyroxine (Sandoz, Mylan, Lannett) costs $4 to $15 per month at retail pharmacies. Armour Thyroid carries a manufacturer list price of approximately $180 per month, though cash-pay prices through discount platforms average $85 per month. On a Medicare Advantage formulary, the plan's negotiated rate falls between these figures.

Clinical Equivalence Debate

The ATA's 2014 hypothyroidism guidelines recommend levothyroxine as first-line therapy based on its consistent potency, long half-life (approximately 7 days), and decades of outcome data [2]. Desiccated thyroid extract contains both T4 and T3 in a fixed ratio (approximately 4.2:1), which does not match the human thyroid's physiologic ratio of roughly 14:1. This difference means patients on Armour Thyroid may have transiently elevated T3 levels after dosing.

When Desiccated Thyroid May Be Preferred

Some patients report improved symptom resolution on desiccated thyroid despite equivalent TSH levels on levothyroxine. A 2020 survey published in the Journal of the Endocrine Society (N=12,146) found that 60.4% of respondents taking desiccated thyroid reported satisfaction with treatment, compared to 46.6% of those on levothyroxine alone [3]. Genetic variation in the deiodinase type 2 enzyme (DIO2 Thr92Ala polymorphism) may explain why some individuals convert T4 to T3 less efficiently, potentially benefiting from exogenous T3. A 2009 study by Panicker et al. In the Journal of Clinical Endocrinology & Metabolism (N=552) found that carriers of the DIO2 Thr92Ala variant had worse psychological well-being on levothyroxine monotherapy [4].

Can You Use a Manufacturer Savings Card with Medicare Advantage?

No. Federal anti-kickback statutes prohibit Medicare beneficiaries from using manufacturer copay cards or savings programs for drugs covered under Part D. This applies to all Medicare Advantage plans with Part D benefits. AbbVie (which markets Armour Thyroid) may offer a patient assistance program for low-income individuals not enrolled in Part D, but beneficiaries receiving Part D coverage are ineligible.

Alternative Cost-Reduction Strategies

Patients facing high copays on Medicare Advantage have several options. The Medicare Extra Help (Low-Income Subsidy) program reduces Part D copays to $4.50 for generics and $11.20 for brand-name drugs for qualifying individuals (income below 150% of the federal poverty level). State Pharmaceutical Assistance Programs (SPAPs) in states like New York, Pennsylvania, and Connecticut provide additional subsidies. Some patients switch to NP Thyroid or WP Thyroid (other desiccated thyroid brands) if their plan covers one at a lower tier, though availability has been inconsistent due to FDA recalls affecting certain lots.

Coverage for Off-Label Uses: Weight Loss and Fatigue

CMS rules are clear: Part D plans cannot cover drugs prescribed solely for weight loss unless the drug holds an FDA-approved indication for a cardiovascular outcome (as with semaglutide 2.4 mg post-SELECT trial). Armour Thyroid is FDA-approved exclusively for hypothyroidism and pituitary TSH suppression [5]. Prescribing it for weight loss in euthyroid patients is off-label and will be denied by every Medicare Advantage plan without exception.

Thyroid Hormone for Subclinical Hypothyroidism

A gray area exists for subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4). The 2019 European Thyroid Association guidelines recommend against routine treatment in patients over 65 with TSH below 10 mIU/L [6], but the ATA acknowledges that treatment may be considered in younger patients with symptoms. Medicare Advantage plans generally approve Armour Thyroid for subclinical hypothyroidism if TSH is above 10 mIU/L. For TSH between 4.5 and 10, PA approval depends on the carrier and the strength of the clinical documentation.

Checking Your Specific Plan's Formulary

Every Medicare Advantage plan publishes its formulary online. The fastest way to confirm Armour Thyroid coverage is to visit Medicare Plan Finder and enter your zip code, plan name, and the drug name. The tool shows tier placement, PA requirements, step therapy rules, and estimated copay. You can also call the number on the back of your Medicare Advantage card and ask the pharmacy benefits department directly.

Annual Formulary Changes

Plans can modify formularies each January 1. A drug on Tier 2 this year could move to Tier 3 or be removed entirely next year. CMS requires plans to notify affected enrollees at least 60 days before a negative formulary change takes effect. Review your Annual Notice of Change (ANOC) document each September to catch any shifts in Armour Thyroid coverage before Annual Enrollment closes on December 7.

Patients currently stable on Armour Thyroid who discover their plan is dropping coverage should consider switching to a Medicare Advantage plan that still covers the drug during the Annual Enrollment Period, or requesting a formulary exception from their current plan before January 1.